BioCentury
ARTICLE | Clinical News

Emergent BioSolutions preclinical data

November 18, 2013 8:00 AM UTC

In a mouse xenograft model of prostate cancer, 3 and 30 µg doses of ES414 led to complete inhibition of tumor growth and a 100% overall survival (OS) rate at day 120. All vehicle-treated control mice ...